Sartorius Set to Double Glasgow Workforce in 2016
News Apr 28, 2016
Sartorius Stedim BioOutsource, a leading provider of contract testing services to the biopharmaceutical industry, is pleased to announce that it is looking to almost double the scientific workforce at its Glasgow facilities in 2016. The new staff will help to meet increasing global demand for the firm’s analytical expertise in testing a wide range of biologics-based drugs and vaccines.
BioOutsource’s facilities in Glasgow have continued to grow since its acquisition by Sartorius Stedim Biotech in 2015. One contributing factor is the expansion in the number of assays developed by BioOutsource’s scientists.
Due to its success, the firm is actively recruiting a number of post-doctoral or PhD scientists. The new staff will work in a modern bioanalytical laboratory environment in areas of large molecule drug analysis, using systems such as a Biacore.
For information on the types of roles available at BioOutsource scientists should click this link: http://ow.ly/4mW7X1
Dr Daniel Galbraith, Chief Scientific Officer of Sartorius Stedim BioOutsource stated: "We’re delighted to be recruiting new scientists because it allows us to harness the skills of the talented researchers being trained in drug discovery at the UK’s outstanding universities. This will allow us to go from strength to strength by consolidating our expertise and building niche bioanalytical skills in Glasgow.”
Galbraith continued: “Expanding our team’s expertise will provide our global pharmaceutical and biotechnology industry clients with excellent quality analytical testing, enabling them to rapidly and cost-effectively enter clinical development with their drugs and vaccines.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018